--- title: "A brain probe softer than tissue itself wants to outlast every rigid implant" date: 2026-11-09 category: Brain–Computer Interface site: NeuroAI canonical: https://neuroai.site/a/na-brain-axoft-soft-electrode-bci language: en --- # A brain probe softer than tissue itself wants to outlast every rigid implant > Axoft's Fleuron probe is up to 10,000× softer than conventional materials and just cleared its first human tests in Panama — pushing biocompatibility over raw bandwidth. Most brain implants are built like tiny rigid rafts dropped onto Jell-O: they record beautifully for a week, then the brain pushes back. Axoft, a Boston neurotechnology company, is betting that the winning move is not more electrodes but a material so soft it disappears into the tissue. This year it put that bet inside real human skulls for the first time. ## An electrode softer than nerve tissue Axoft's core asset is Fleuron, a proprietary polymer that the company says is up to 10,000 times softer than the polyimide used in conventional implantable probes. The claim is mechanical, not marketing spin: rigid and even "flexible" electronics still move relative to brain tissue, which triggers inflammation, scarring and the signal drift that eventually blinds a chronic implant. A probe that matches the brain's own softness is meant to sit quietly for years. The implant is delivered through a roughly 2-millimeter burr hole using standard neuronavigation — a minimally invasive entry that avoids the large craniotomy some competitors need. It is designed for high-density, bidirectional recording and stimulation, feeding an AI decoding layer the company calls a "brain foundation model." ## From Stanford-licensed IP to a $55M raise Axoft was founded in 2021 and built on academic research, with the Fleuron intellectual property exclusively licensed from Stanford University. In October 2025 it closed a $55 million Series A led by C.P. Group Innovation, with Alumni Ventures, the Stanford President's Venture Fund, Hillhouse Investment (高瓴投资) and Gaorong Ventures (高榕创投) participating, according to public funding records and trade coverage. That lifted total disclosed funding past $60 million, on top of an $8 million seed round in 2022 led by The Engine. The presence of Hillhouse and Gaorong — two China-based venture firms — is more than a cap-table curiosity: it gives Axoft a direct line to Asian regulatory and clinical markets, an increasingly important advantage as implantable brain-computer interface (脑机接口) move toward global trials. ## First humans, in Panama Before the raise, Axoft ran its first-in-human feasibility study, registered as NCT06673264, at the Panama Clinic (CEVAXIN) in Panama City. Running from March 14 to August 21, 2025, the interventional study enrolled five participants already scheduled for brain-tumor or epileptic-tissue removal surgery. Surgeons inserted the soft probe into tissue destined for resection to test safe placement, signal recording and tissue response. Harvard's Office of Technology Development, which helped shepherd the startup, reported that the implant proved safe to insert and remove and produced no added risk to the brain — and that within minutes it could tell whether a patient was conscious or under anesthesia, a proxy for coma-like states that normally takes an fMRI scan hours to assess. Results have not been formally published, but completing the trial is a real regulatory milestone. ## The first target: disorders of consciousness Axoft's near-term clinical aim is disorders of consciousness. The roadmap runs in three steps: first use the implant to measure a patient's level of consciousness and estimate the chance of awakening; then help brain-injury survivors communicate through a computer during recovery; and ultimately use the device to support rehabilitation. It is a slower, more conservative path than chasing speech or movement restoration, but one chosen for clearer regulatory traction. The company is also building a GMP manufacturing facility in the Boston area and advancing its U.S. FDA engagement, while selling Fleuron material to research and industrial users as a parallel revenue track. According to Li An, chief scientist at BrainNet (脑机网), the 2025–2026 wave of implantable BCIs shows "the non-invasive and minimally invasive routes are no longer the niche — they are becoming the mainstream path for the first approved uses." Axoft's soft-material approach is a clear expression of that trend. ## Honest limitations Key figures here — the $55M round, the October 2025 date, the NCT number and the five-participant Panama study — come from funding databases, company materials and trade press (Nova Pharma News, TAMradar), not from a peer-reviewed publication; the Panama results are not yet publicly detailed. The "10,000× softer" claim is the company's stated specification and has not been independently benchmarked in this article. Axoft's specific plans for China trials are not confirmed in authoritative sources; the China link here is inferred from its investor roster, not from an announced clinical program. Long-term biocompatibility in chronic human implants remains unproven. ## What readers can do now - If you follow neurotechnology investing, note that Asian venture capital (高瓴, 高榕) is now a structural backer of U.S. BCI hardware — a signal worth tracking for where trials may expand. - Researchers can access Fleuron material commercially today for lab use, separate from any implant pathway. - Patients and families should treat Axoft's consciousness and communication work as early-stage; ask any trial site for the ClinicalTrials.gov identifier (NCT06673264) before weighing participation. ## Key takeaways - Axoft's Fleuron probe is up to 10,000× softer than legacy materials, targeting chronic signal stability rather than maximum channel count. - A $55M Series A (Oct 2025) and a completed five-patient Panama feasibility study (NCT06673264) mark real progress. - With Chinese VCs on the cap table, the company is positioned for global, including Asia, clinical expansion. --- Published by NeuroAI (https://neuroai.site/) — https://neuroai.site/a/na-brain-axoft-soft-electrode-bci Free to quote with attribution and a link to the original.